Breaking Finance News

QIAGEN (ETR:QIA) target price raised to 31.00EUR, issued a report today by Kepler Cheuvreux

Yesterday QIAGEN (ETR:QIA) traded 0.00% even at 26.95EUR. The company’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. The last closing price is up 0.00% from the 200-day moving average, compared to the S&P 500 which has increased 0.06% over the same time. 0 shares of the stock were exchanged, down from an average trading volume of 0

QIAGEN (ETR:QIA) had its target price raised to 31.00EUR by Kepler Cheuvreux in a report released Friday February 17, 2017. The new target price indicates a possible upside of 0.15% based on the company's last closing price.

Previously on 02/16/2017, Kepler Cheuvreux reported on QIAGEN (ETR:QIA) raised the target price from 0.00EUR to 31.00EUR. At the time, this indicated a possible upside of 0.14%.

See Chart Below


QIAGEN has a 52 week low of 0.00EUR and a 52 week high of 0.00EUR The company’s market cap is currently 0 EUR.

General Information About QIAGEN (ETR:QIA)

QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Its bioinformatics solutions interpret data to provide actionable insights. Its automation platforms tie these together in molecular testing workflows-from Sample to Insight. Its Sample to Insight molecular technologies are applicable across a range of applications and customer classes through over 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. Its bioinformatics solutions include the Ingenuity, CLC bio, OmicSoft and BIOBASE portfolios. The Company, through OmicSoft Corporation (OmicSoft), offers solution across the data management and interpretation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.